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Abstract
Understanding how hepatitis C virus (HCV) induces and circumvents the host’s natural killer (NK) cell-mediated immunity is
of critical importance in efforts to design effective therapeutics. We report here the decreased expression of the NKG2D
activating receptor as a novel strategy adopted by HCV to evade NK-cell mediated responses. We show that chronic HCV
infection is associated with expression of ligands for NKG2D, the MHC class I-related Chain (MIC) molecules, on hepatocytes.
However, NKG2D expression is downmodulated on circulating NK cells, and consequently NK cell-mediated cytotoxic
capacity and interferon-c production are impaired. Using an endotoxin-free recombinant NS5A protein, we show that NS5A
stimulation of monocytes through Toll-like Receptor 4 (TLR4) promotes p38- and PI3 kinase-dependent IL-10 production,
while inhibiting IL-12 production. In turn, IL-10 triggers secretion of TGFb which downmodulates NKG2D expression on NK
cells, leading to their impaired effector functions. Moreover, culture supernatants of HCV JFH1 replicating Huh-7.5.1 cells
reproduce the effect of recombinant NS5A on NKG2D downmodulation. Exogenous IL-15 can antagonize the TGFb effect
and restore normal NKG2D expression on NK cells. We conclude that NKG2D-dependent NK cell functions are modulated
during chronic HCV infection, and demonstrate that this alteration can be prevented by exogenous IL-15, which could
represent a meaningful adjuvant for therapeutic intervention.
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Introduction
Natural Killer (NK) cells are effectors of the rapidly acting
antiviral innate immune system. They kill virally infected cells and
are an important source of antiviral cytokines such as IFNc.I n
addition, they establish an early and efficient dialogue with
professional antigen presenting cells (APCs) that in turn,
orchestrate the adaptive immune response towards Th1-type
antiviral immunity [1]. NK cell activation is tightly regulated by
the integration of signals emanating from a diverse array of
inhibitory and activating receptors [2]. Inhibitory receptors,
including Killer cell Immunoglobulin-like receptors (KIRs) and
CD94/NKG2A, gauge expression of MHC class I molecules
which can be compromised by viral immune subversion, and thus
serves as an indicator of the integrity of cells. Activating receptors,
including the natural cytotoxicity receptors (NCRs) and NKG2D,
usually detect the presence of infectious non-self and/or stress-
induced self ligands at the surface of infected cells.
Hepatitis C virus (HCV), which replicates in hepatocytes,
mediates a chronic liver infection in the majority of infected
individuals. NK cells abound in the normal liver, where they make
up to 30% of resident hepatic lymphocytes [3]. This huge amount
of NK cells in the liver suggests that they are important sentinel
cells, surveying the liver for signs of damage or cellular stress.
However, it also implies that HCV must divert NK cell-mediated
responses in order to establish persistent infection. The importance
of NK cells in the resolution of HCV infection is illustrated by the
influence of genetic polymorphisms of KIR and their HLA ligands
on the outcome of HCV infection [4]. Various alterations of NK
cell phenotype have been described during chronic HCV
infection, but results are often contradictory regarding the
experimental conditions used (ex vivo or in vitro cytokine-
stimulated), the modifications involved and their consequences
on effector functions [5,6,7,8,9,10,11].
The NKG2D activating receptor is constitutively expressed on
human NK and CD8 T cells [12]. Its ligands, the MHC class I
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binding proteins (ULBP1–4), are almost undetectable in normal
tissues, but are induced on the cell surface by various stresses such
as DNA damage, tumor transformation and intracellular infection.
The importance of the NKG2D defense system is highlighted by
the observation that tumors and viruses have developed several
mechanisms for evading NKG2D-mediated recognition
[13,14,15,16,17]. The overall contribution of the NKG2D
pathway in the control of HCV infection is unclear [7,10]. We
show here that NKG2D is downmodulated on circulating NK
cells, and consequently NK cells are functionally impaired. This
defect is mediated by the HCV-NS5A protein, which disturbs the
equilibrium between pro- and anti-inflammatory monocyte-
derived cytokines.
Results
NKG2D expression is decreased on circulating NK cells
during chronic HCV infection
MIC proteins are induced at the cell surface upon exposure to
various pathogens [11,18,19,20], serving as a warning signal that
alerts NK cells to mediate effector functions through NKG2D
signaling. We thus examined if MIC was expressed in the liver
during chronic HCV infection. While staining of control livers
showed a faint expression of MIC in the cytoplasm of some
hepatocytes and Kupffer cells only, HCV-infected livers displayed
a strong and diffuse expression of MIC in the cytoplasm and at the
surface of HCV-infected hepatocytes, and also in some uninfected
hepatocytes and large mononuclear cells in portal spaces
resembling macrophages (Figure 1).
NKG2D is constitutively expressed on NK cells, and should
therefore mediate recognition and destruction of MIC-expressing
cells. Due to the restricted availability of fresh HCV-infected liver
samples to isolate infiltrating NK cells, we examined the
expression of NKG2D on circulating NK cells. No significant
difference in the percentage of circulating NK cells, or in the
proportion of CD56
bright/CD56
dim cells was detectable between
patients and controls (data not shown). The percentage of
NKG2D-expressing NK cells was similar in HCV patients and
healthy controls (.95% of NK cells in both groups). However, a
decreased expression of NKG2D on both CD56
bright and
CD56
dim NK cells was detected in HCV viremic patients as
compared with healthy controls (mean MFI: 61615 versus
93625, P,10
24), HCV patients with sustained viral response
(SVR) after treatment (81614, P,10
23) or patients with non-
infectious chronic inflammatory liver disease (87.4624.5,
P,10
23) (Figure 2A). Although showing some variability among
viremic patients, NKG2D levels were not correlated with age, sex,
HCV viral load, genotype, ALT levels, liver fibrosis or activity
score.
To evaluate the functional consequences of this NKG2D
reduction, we quantified NK cell IFNc production and CD107a
degranulation by flow cytometry. Freshly purified circulating NK
cells from HCV patients showed impaired IFNc production in the
presence of MHC class I-negative K562 as compared to NK cells
from healthy controls. In addition, NK cells from HCV patients
showed a two-fold decreased degranulation in the presence of
K562 targets (mean CD107 expression 29.3%62.7 in controls
compared to 15.9%62.9 in patients, P=0.003) (Figure 2B). This
defective NK cell function was at least in part dependent on
NKG2D, as shown using C1R-MICA as target cells. CD107a
expression on NK cells positively correlated with NKG2D levels
(Spearman rho (r) =0.62, P=0.008, Supplementary Figure S1).
Moreover, NKG2D blocking by anti-NKG2D antibody largely
inhibited inhibited NK cell degranulation in both HCV patients
and healthy controls (Figure 2C). That NK cell degranulation was
not fully abrogated indicates however, that it likely involves other
activating receptor(s) in addition to NKG2D. Altogether, these
results suggest that the signaling pathway initiated by NKG2D on
target exposure may not operate properly in HCV patients due to
NKG2D reduction on NK cells.
Soluble TGFb is associated with NKG2D reduction
Systemic NKG2D downregulation on immune effector cells has
been related to the release of soluble factors such as MIC
molecules (sMIC) in the serum of cancer patients [13]. We
measured sMIC in the serum of HCV patients and healthy
controls, and found similar low levels of sMIC in both groups (data
not shown). TGFb is another mediator of systemic NKG2D
downregulation [21,22,23]. Total TGFb levels were higher in the
serum of HCV-infected patients compared to controls and SVR
patients (Figure 3A). An inverse linear relationship was observed
between TGFb and NKG2D levels on NK cells (Figure 3B). To
investigate whether serum of HCV patients could mimic the effect
of exogenous TGFb on NKG2D expression, we incubated control
NK cells with recombinant TGFb or with serum from represen-
tative HCV patients with known TGFb concentration, and
analyzed NKG2D expression. NKG2D levels were reduced in a
TGFb concentration-dependent manner, and were largely re-
stored when incubation was performed in the presence of
neutralizing anti-TGFb antibody (Figure 3C).
TGFb is secreted by monocytes upon stimulation by the
HCV-NS5A protein
Engagement of the HCV receptor CD81 by the major HCV
envelope protein E2 was shown to block NK cell functions
triggered by NKG2D engagement [24]. We thus hypothesized
that HCV-E2 might modulate NKG2D expression. PBMCs from
normal donors were exposed to recombinant HCV-E2, as well as
to other structural and non-structural HCV proteins for 6 to
48 hr, and NKG2D levels were measured on NK cells (Figure 4A).
While HCV-E2, -core, -NS3, or -NS4 proteins had no or minor
Author Summary
Natural killer (NK) cells are part of the innate immune
response against virus infection. Their activation is the net
result of signals emanating from a panel of inhibitory and
activating receptors, among which the NKG2D activating
receptor plays a major role. NKG2D ligands, the MHC class I
related Chain (MIC) molecules, are induced on HCV-
infected hepatocytes. In this paper, we show that NKG2D
expression is decreased on NK cells from chronically
infected HCV patients. As a consequence, NK cell cytolytic
and IFNc-producing functions are impaired. We show that
this phenomenon is mediated by TGFb produced by
monocytes upon stimulation by the non-structural HCV-
NS5A protein. NS5A could bind to TLR4 on monocytes,
thus inducing the production of IL-10 and TGFb, while
inhibiting the production of IL-12. We further showed that
TLR4-dependent IL-10 production by monocytes upon
NS5A stimulation was mediated through the p38 and PI3
kinase pathways. In addition, we demonstrated that IL-15
could inhibit the TGFb-mediated effects on NKG2D
expression and NK cell functions. Collectively, these results
identify a new dampening signal used by HCV to subvert
innate immune response, and may provide new insights
into the design of new strategies to restore NK cell
functions in chronic hepatitis C.
HCV Evasion to NKG2D-Mediated Response
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on NK cells, which was maximal at 48 hr. Using different
recombinant NS5A preparations (E. Coli-derived full length NS5,
yeast-derived NS5 2054-2995 or E. Coli-derived NS5A amino
acid 2061–2392), we reproducibly identified the NS5A protein as
being responsible for this effect. At a concentration of 0.5 mg/ml,
NS5A reduced NKG2D expression by 40% (P=0.001), which was
of the same order of magnitude as 10 ng/ml of recombinant
TGFb used as positive control. Of note, NS5A stimulation also
induced downmodulation of the NKp30 activating receptor
(Supplementary Figure S2), in line with the previously described
effect of TGFb on NKp30 expression [23]. The b2-microglobulin,
used as control for irrelevant protein produced in E. Coli, had no
effect on NKG2D expression. All recombinant proteins used were
tested for the absence of significant lipopolysaccharide (LPS)
contamination (0.054 endotoxin unit/mg recombinant protein in
the case of NS5A, i.e. 5.4 pg/mg protein). In addition, pretreating
NS5A by 10 mg/ml of polymyxin B was without effect, ruling out
the possibility of contaminating LPS being the factor responsible
for NKG2D reduction. Inactivation of the NS5A protein by
freeze/thaw before incubation with PBMCs abolished the NS5A-
mediated NKG2D reduction, suggesting that it required intact
protein conformation.
To verify that NS5A-mediated downregulation of NKG2D on
NK cells was accompanied by a decrease in their functional
capacity, PBMCs were exposed to NS5A, NS4 or medium alone
for 48 h, after which NK cell degranulation capacity in the
presence of K562 target cells was evaluated by flow cytometry.
The presence of NS5A in PBMC culture induced a significant
decrease of CD107a expression on NK cells, while NS4 had no
effect, confirming that NS5A is responsible for a decreased
functionality of NK cells (Figure 4B).
We then measured the TGFb concentration in culture
supernatants from PBMCs exposed to NS5A or medium alone
for 12 to 48 h. Levels of TGFb progressively increased in the
presence of NS5A (Figure 4C). To confirm that the NS5A effect
was indeed related to TGFb production, we pretreated PBMCs
with anti-TGFb antibody prior to stimulation with NS5A.
Blocking TGFb abrogated the NS5A-induced reduction of
NKG2D on NK cells in a dose-dependent way (Figure 4D).
When similar experiments were performed on freshly purified
NK cells, NS5A stimulation failed to downmodulate NKG2D,
suggesting that TGFb was likely produced by a distinct cell
population among PBMCs. To identify the source of TGFb,w e
cocultured purified NK cells with different components of
autologous PBMCs, including adherent or non-adherent cells,
monocyte-depleted PBMCs, or purified monocytes. Cells were
stimulated for 6–48 hr with NS5A, after which NKG2D was
measured on NK cells. At the same times, culture supernatants
were recovered and were assayed for TGFb production. As shown
in Figure 4E, only monocyte-containing populations induced a
significant decrease of NKG2D expression on NK cells (p,0.002).
Notably, downregulation of NKG2D was completely lost in the
Transwell system, indicating that monocyte-NK cell contacts were
required for this effect. NKG2D reduction was accompanied by an
increased production of TGFb in cell supernatants, which was
Figure 1. MIC proteins are overexpressed in HCV-infected liver. Staining for MIC proteins in sections of paraffin-embedded (A–D) or
cryopreserved (E, F) liver biopsies from HCV-negative control (A) or chronically HCV-infected patients (B–F). Control isotype is shown in (D). A strong
and diffuse expression of MIC (red) is observed in hepatocytes from HCV-infected patients, in the cytoplasm (B, C) and at the membrane (E, confocal
microscope analysis). MIC expression is seen in HCV infected cells (NS5A staining in green) and in some adjacent cells (F). Nuclei appear colored in
blue. Results are representative of 12 patients for paraffin-embedded biopsies, and 3 patients for cryopreserved biopsies. Original magnification,610
(A, D), 640 (E) and 660 (F).
doi:10.1371/journal.ppat.1001184.g001
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PLoS Pathogens | www.plospathogens.org 3 November 2010 | Volume 6 | Issue 11 | e1001184Figure 2. NKG2D levels and NK cell functions are altered in HCV-infected patients. A) Freshly isolated PBMCs were stained with CD56, CD3
and NKG2D mAbs, and analyzed by FACS. Gating on CD3-CD56+ cells identified NK cells. Left panel: Representative NKG2D staining in one healthy
control (dark line), one chronically-infected HCV patient (plain gray) and one HCV patient with sustained viral response (SVR, empty gray). Isotype
control is shown in dotted line. Right panel: Combined data showing the mean NKG2D levels on NK cells from 23 controls, 41 HCV patients, 9 patients
with SVR, and 9 patients with non-infectious inflammatory liver disease (ILD). Data are expressed as box plots, in which the horizontal lines illustrate
the 25
th,5 0
th, and 75
th percentiles of the MFI of NKG2D. The vertical lines represent the 10
th and 90
th percentiles. * P,10
24,* *P,10
23. B) Frequency
of CD107a+ degranulating (left panel) or IFNc-producing (right panel) NK cells incubated for 6 hr in medium alone, or in the presence of MHC class I-
negative K562 cells (E:T ratio 1:1). Results show the mean 6 SEM values in 11 HCV patients and 15 healthy controls. * P=0.003. C) Frequency of
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neutralization of TGFb in the coculture system of monocytes and
NK cells fully restored NKG2D expression on NK cells.
Altogether, these results indicate that NS5A protein induces
TGFb production by monocytes, which in turn affects NKG2D
expression and inhibits NK cell functions.
Figure 3. TGFb is overproduced in HCV patients, and mediates NKG2D reduction on NK cells. A) The levels of total TGFb were
significantly higher in serum from 34 HCV patients compared to 23 controls (* P=0.008). Only 4 samples from SVR patients could be analyzed. B)
Inverse correlation between serum TGFb levels and NKG2D levels on NK cells in HCV patients. Pearson’s correlation coefficient r=20.49, P=0.004. C)
NKG2D levels are reduced in a TGFb-dependent manner. NK cells were cultured in medium alone, or in medium containing 10% serum from
representative HCV patients with known TGFb concentration (S1: 6 ng/ml, i.e. 0.6 ng/ml final concentration; S2: 32 ng/ml, i.e. 3.2 ng/ml final
concentration), or in medium containing 10 ng/ml of recombinant TGFb. NKG2D expression was analyzed 24 hr later by flow cytometry. Addition of
10 mg/ml of neutralizing anti-TGFb mAb during incubation largely reversed NKG2D reduction. Results are expressed as NKG2D levels on NK cells
cultured in each indicated condition relative to the levels on NK cells cultured in medium alone, and represent mean 6 SEM of 2 independent
experiments. P=0.02 for all comparisons (Kruskall Wallis test).
doi:10.1371/journal.ppat.1001184.g003
CD107a+ NK cells incubated for 6 hr with K562 cells (alone or in the presence of 20 mg/ml of NKG2D blocking mAb or control IgG), C1R cells or C1R-
MICA transfectants. E:T ratio 1:1. Left panel: Combined data in 6 HCV patients (grey bars) and 6 healthy controls (white bars). * P=0.003, ** P=0.0001.
Right panel: Dot plots show a representative experiment in one control (upper line) and one HCV patient (lower line). Numbers in the quadrant
indicate the percentage of CD107a+ NK cells.
doi:10.1371/journal.ppat.1001184.g002
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PLoS Pathogens | www.plospathogens.org 5 November 2010 | Volume 6 | Issue 11 | e1001184Figure 4. HCV-NS5A protein mediates TGFb-induced downmodulation of NKG2D. A) Control PBMCs (0.2610
6/ml) were stimulated with
HCV-core, -E2, -NS3, -NS4, -NS5A or b2 microglobulin proteins at 0.1 mg/ml (white bars), 0.5 mg/ml (gray bars), or 1 mg/ml (black bars), or with
recombinant TGFb (10 ng/ml) for 48 h, and NKG2D expression was analyzed on CD3-CD56+ NK cells. Results are expressed as the percentage of
HCV Evasion to NKG2D-Mediated Response
PLoS Pathogens | www.plospathogens.org 6 November 2010 | Volume 6 | Issue 11 | e1001184NS5A augments IL-10 and suppresses IL-12 production
by monocytes
Activation of monocytes by microbial products usually induces
the production of IL-12, and to a lesser extent of IL-10. We thus
wondered if the ability of NS5A to regulate the production of
TGFb was more global, and measured the production of IL-10
and IL-12 in supernatants from control monocytes stimulated for
24 to 48 h with NS5A, NS4, medium alone, or LPS as a positive
control. High levels of IL-10 (.1400 pg/ml) were detected 24 hr
after NS5A stimulation (Figure 5A, left panel). These levels were of
the same order of magnitude as those induced by 1 mg/ml of LPS.
We then wondered if NS5A-induced TGFb production was
related to autocrine IL-10 release. Blocking IL-10 or its receptor
abrogated the NS5A-induced TGFb secretion in a dose-dependent
manner, but did not modify the basal TGFb production by
monocytes (Figure 5A, right panel). Furthermore, we found
elevated IL-10 levels in the sera of HCV patients, that were
positively correlated with TGFb levels (r=0.39, P=0.016).
By contrast, very low amounts of IL-12 were detected in
supernatants of NS5A-stimulated monocytes, while LPS induced
high levels of IL-12 as expected (Figure 5B). We thus hypothesized
that NS5A might inhibit the LPS-induced production of IL-12 by
monocytes. Indeed, pretreatment of monocytes by NS5A strongly
inhibited IL-12 production upon LPS stimulation.
Taken together, these findings demonstrate that NS5A potently
increases the production of anti-inflammatory cytokines IL-10 and
TGFb, while concurrently suppressing the production of proin-
flammatory IL-12. The lack of NS5A-induced IL-12 secretion also
confirms that LPS contamination is not responsible for the NS5A-
mediated effect in monocytes.
NS5A interaction with TLR4 instructs monocytes to
preferentially induce IL-10 secretion
NK cell activation requires signals provided by APCs that sense
pathogen products through conserved pattern-recognition recep-
tors such as Toll-like receptors (TLRs). In particular, TLR2 and
TLR4 are involved in extracellular sensing of several viral proteins
by monocytes and dendritic cells [25,26,27]. We thus hypothesized
that NS5A might interact with TLR2 or TLR4 signaling in
monocytes. Pretreating monocytes with blocking anti-TLR4
antibody, or with antibody to the TLR4 associated molecule
CD14, fully abolished NS5A-mediated IL-10 production, while
blocking anti-TLR2 antibody had no effect (Figure 5C). This
suggested that NS5A might interact with TLR4 on monocytes. To
support this hypothesis, freshly purified monocytes were incubated
at 4uC with NS5A or NS4, and binding was revealed by staining
with anti-NS5A antibody and flow cytometry analysis. A
significant binding of NS5A on monocytes was observed, that
was inhibited by almost 50% in the presence of blocking anti-
TLR4 antibody (Figure 5D).
TLR4 signaling results in the downstream activation of NF-kB,
MAPK (p38 and JNK) and PI3K pathways[28]. TLR4 activation
may contribute to IL-10 production via p38 and PI3K [29], while
PI3K is an endogenous suppressor of IL-12 production triggered
by TLR4 [30]. We pretreated monocytes with pharmacological
inhibitors of signaling molecules prior to stimulation with NS5A,
and measured IL-10 production. Inhibition of p38 or PI3K
suppressed NS5A-induced production of IL-10 in a dose-
dependent way, while other inhibitors had no or minor effects
(Figure 5E).
Altogether, our results indicate that, upon NS5A interaction
with TLR4, monocytes preferentially secrete IL-10 through
activation of the p38 and PI3 kinase pathways, but are prevented
from secreting IL-12.
NS5A mediates the NKG2D-downregulating effect in
supernatants of HCV-infected cells
NS5A is not found in viral particles secreted by infected cells,
which raises the question of its availability in the extracellular
medium. However, it is becoming increasingly clear that HCV
infection of hepatocytes has direct cytopathic effects, suggesting
that NS5A might be released from apoptotic/necrotic infected
cells [31,32,33]. To verify this hypothesis, we determined whether
supernatants of HCV-infected cells induced downmodulation of
NKG2D. To this aim, we used Huh-7.5.1 hepatoma cells
transfected or not with the infectious genotype 2a JHF1 replicon
[34,35]. Control PBMCs were cultured for 48 h with Huh-7.5.1
culture supernatants or with recombinant NS5A as positive
control, after which NKG2D levels on NK cells were measured
(Figure 6A). Supernatants from Huh-7.5.1 uninfected cells, or
those recovered as soon as day 3 post transfection, did not modify
NKG2D levels. By contrast, supernatants recovered on days 13,
15 and 18 post transfection reproducibly induced downmodula-
tion of NKG2D at levels similar to those obtained using 0.5 mg/ml
rNS5A. At these time points, the majority of cells in the culture
expressed HCV proteins, infectivity titers in culture supernatant
were maximal, and cytopathic effects were observed, as reported
[31]. Notably, there was no effect of supernatants recovered at day
23, i.e. at a time cells were cytologically normal and levels of
extracellular infectious virus had declined.
To rule out the possibility that this effect was mediated by
TGFb, we quantified TGFb in Huh-7.5.1 culture supernatants. In
all conditions studied, TGFb levels were below 40 pg/ml and
could thus not be responsible for the observed NKG2D-
downregulating activity. Taken together, these data indirectly
suggested that NS5A is released by HCV-replicating cells, most
likely among cell debris generated by infection.
Since we previously observed a specific binding of recombinant
NS5A on monocytes, we incubated control PBMCs with
supernatants from uninfected or infected Huh-7.5.1 cells, or with
recombinant NS5A or NS4 proteins, after which NS5A binding to
inhibition of NKG2D expression in each condition relative to medium alone. Mean 6 SEM of 3 independent experiments are shown. * P=0.001. B)
NS5A-mediated decrease in NK cell lytic potential. Control PBMCs were exposed to NS5A, NS4 or medium alone for 48 h, after which NK cell lytic
potential to K562 target cells was evaluated by flow cytometry (CD107a expression). * P=0.008. C) Kinetic analysis of TGFb secretion upon 48 h
stimulation of PBMCs (circles) or purified monocytes (squares) with 0.5 mg/ml of NS5A. TGFb concentrations are given after background subtraction
(cells cultured in medium alone). D) Pretreatment of PBMCs with increasing (0.01–3 mg/ml) concentrations of neutralizing TGFb mAb prior to
incubation with NS5A induces a dose-dependent increase of NKG2D on NK cells. E) Monocytes are the source of TGFb upon NS5A stimulation. Left
panel: The indicated cell populations were stimulated with 0.5 mg/ml of NS5A for 40 hr after which NKG2D expression was evaluated on NK cells.
Results are expressed as NKG2D levels on NK cells in the indicated condition relative to the values in medium alone. NK cells were cultured with
purified monocytes at the ratio of 1:1 with or without Transwell (0.4 mm) separation or in the presence of 10 mg/ml anti-TGFb mAb or isotype Ab.
Data are mean 6 SEM of 3 independent experiments. * P,0.002 for comparison with the values in medium alone. Right panel: Supernatants were
harvested and assayed for TGFb content. Values are normalized to TGFb produced by cells cultured in medium alone and represent the mean 6 SEM
of 4 independent experiments. * P=0.006, ** P=0.0003.
doi:10.1371/journal.ppat.1001184.g004
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PLoS Pathogens | www.plospathogens.org 7 November 2010 | Volume 6 | Issue 11 | e1001184Figure 5. NS5A induces IL-10 and suppresses IL-12 production by monocytes through TLR4-mediated activation of p38 and PI3
kinase signaling. A) Left panel: Control monocytes (0.1610
6/ml) were cultured in medium alone, or in the presence of NS4 (0.5 mg/ml), NS5A
(0.5 mg/ml), LPS (1 mg/ml), or NS5A+LPS for 24 hr, and cell supernatants were analyzed for IL-10 by ELISA. Data are expressed as the mean 6 SEM of
three independent experiments. * P=0.01. Right panel: Monocytes were pretreated with IL-10 neutralizing mAb or soluble IL-10 receptor prior to
HCV Evasion to NKG2D-Mediated Response
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Supernatants from uninfected cells, or supernatants recovered on
days 2 and 23 post transfection did not show any binding signal, in
accordance with their lack of NKG2D-downregulating activity.
However, supernatants recovered on day 12 post transfection gave
a binding signal that was of the same order of magnitude than that
observed with recombinant NS5A (Figure 6B). Notably, this effect
was abrogated when day 12 supernatants were filtered in order to
eliminate cell debris, suggesting that NS5A was not released from
JHF1-replicating Huh-7.5.1 cells in a soluble form, but was rather
associated with apoptotic-cell components. Our attempts to
corroborate the presence of NS5A in day 12 supernatants using
ELISA or Western blot techniques, or to deplete NS5A from these
supernatants using anti-NS5A antibody, were unsuccessful (data
not shown). This could be due to the fact that NS5A was not easily
recognized by the 9E10 mAb when associated with apoptotic cell
debris in the supernatants. Alternatively, it could be that a fraction
of bioactive NS5A becomes liberated after interaction of the cell
debris with monocytes.
Liver NK cells paradoxically express high NKG2D levels
Given that apoptotic HCV-replicating cells seem to release
NS5A, we made an effort to resolve the issue of NKG2D
expression on NK cells in the infected liver. We analyzed liver-
infiltrating NK cells and paired circulating NK cells in 11
additional HCV viremic patients who underwent liver biopsy for
diagnostic purpose. NKG2D levels on peripheral NK cells fully
matched with those in the first series of patients (MFI 59 67.7 and
61615, respectively). Of note, the proportion of NK cells among
liver-infiltrating mononuclear cells was very low (2.7%60.7%), as
already reported in HCV-infected livers [9,36,37]. To our surprise
- but in line with previous observations in the rat and human
([10,38,39]- liver NK cells expressed higher NKG2D levels than
their circulating counterpart (mean MFI 115.5 617.4 versus
5967.7, P=0.002, Wilcoxon matched-pairs test). NKG2D
analysis in a representative liver sample is shown in Figure 6C
(left panel) and Supplementary Figure S3. By comparison,
NKG2D levels on liver NK cells from 8 control patients with
non-infectious chronic inflammatory liver disease were not
significantly different from those observed on circulating NK cells
(mean MFI 106.2 and 87, respectively). Staining of HCV-infected
liver sections showed that NKG2D+ cells were indeed very scarce
even among large portal infiltrates. Only few cells were found
positive in sinusoidal tracts (Figure 6C, right panel). Similar to
what was observed for circulating NK cells, the proportion of liver
NK cells and their NKG2D levels were not correlated with any
HCV disease marker (not shown).
Whether these intrahepatic NKG2D
high NK cells were more
functionally competent than their circulating counterpart could
not be evaluated due to their too small number. In attempt to
analyze NKG2D-mediated functions in a clinically relevant target
cell system, we sought to use JHF1-infected Huh-7.5.1 cells.
However, it turned out that these cells were not pertinent for
NKG2D ligand expression studies. Not only HCV infection did
not induce MIC expression on Huh7.5.1 cells, but none of the
stimuli known to be potent inducers of NKG2D ligands (heat-
shock, oxidative stress, c-radiation, retinoic acid, inhibitors of
histone deacetylase) was able to induce MIC surface expression on
Huh7.5.1 cells (data not shown).
IL-15 can antagonize the TGFb-mediated modulation of
NKG2D and NK cell functions
In contrast with TGFb, IL-15 up-regulates surface NKG2D
expression [40]. Because of the reciprocal antagonism of IL-15
and TGFb on intracellular signaling pathways [41,42,43], we
wondered if decreased NKG2D expression on circulating NK cells
from HCV patients might be amplified by a resistance of NK cells
to endogenous IL-15 due to TGFb or by a defective production of
IL-15 in response to infection. PBMCs from healthy controls or
HCV patients were pretreated with IL-15 for 24 hr after which
NKG2D staining was performed (Figure 7A). IL-15 restored
NKG2D expression on patients’ NK cells at levels similar to those
usually observed in controls, indicating that NK cells from HCV
patients were normally responsive to IL-15. Moreover, IL-15 fully
antagonized the NS5A-induced downmodulation of NKG2D on
NK cells. Even in the presence of TGFb-containing serum, IL-15
could prevent NKG2D expression. Furthermore, both NK cells
from HCV patients and TGFb-stimulated control NK cells
exhibited a significant enhancement of cytotoxicity upon IL-15
stimulation (Figure 7B).
Given that pathogen components are among the stimuli that
elicit production of IL-15, one could expect elevated levels of IL-
15 in the serum of chronic HCV patients. IL-15 levels were not
higher in patients than in controls (mean 7.6161.93 pg/ml, and
7.9861.40 pg/ml, respectively; ns). It must be noted, however,
that IL-15 is mostly present in membrane-bound IL-15/IL-15Ra
complexes [44], so that free IL-15 is unlikely to represent a reliable
marker of systemic IL-15 production.
Altogether, these data suggest that overexpression of TGFb
contributes to the reduction of NKG2D and defective functions of
circulating NK cells in HCV patients, a defect which can be
antagonized by exogenous IL-15.
Discussion
HCV uses a repertoire of dampening signals to subvert immune
responses, a significant number of which target the innate system
[45,46]. We report here an altered expression of the NKG2D
receptor as an additional HCV strategy to avoid NK-cell mediated
recognition. HCV-NS5A protein, through monocyte-derived
stimulation with NS5A, and TGFb levels in the culture supernatants were quantified by ELISA. Results are expressed as index of inhibition of NS5A-
mediated TGFb levels, calculated as: [(TGFb (NS5A) - TGFb (NS5A+mAb))/TGFb (NS5A) - TGFb (medium)]x100, and are the mean 6 SEM of three
independent experiments. * P=0.02, ** P=0.0005. B) For IL-12p70 production, monocytes were first primed by IFNc for 16 h and then stimulated
with LPS (1 mg/ml), HCV-NS5A (0.5 mg/ml) or both for 24 hr, after which supernatants were analyzed for IL-12 by ELISA. Data are expressed as the
mean 6 SEM of three independent experiments. * P=0.02, ** P=0.001. C) Purified monocytes were pretreated with 5 mg/ml of anti-TLR4, -TLR2 or
-CD14 neutralizing antibodies prior to 24 hr stimulation with 0.5 mg/ml of NS5A, after which IL-10 levels in the supernatants were measured by ELISA.
Results are the mean 6 SEM of IL-10 levels from mean replica values in 3 independent experiments. * P=0.02, ** P=0.01. D) Binding of NS5A to
monocytes. Control monocytes were incubated for 30 min at 4uC with 0.5 mg/ml of recombinant NS5A, NS4 or medium alone. Binding of NS5A to
monocytes was revealed by staining with anti-NS5A 9E10 antibody and flow cytometry analysis. Results are expressed as the percentage of positive
cells, and are the mean of 4 independent experiments. E) Monocytes were left untreated, or treated with JNK inhibitor (SP600125, 10 mM), MEK
inhibitor (U0126, 10 mM), PI3K inhibitor (LY294002, 1–50 mM), p38 inhibitor (SB203580, 0.1–10 mM) or DMSO alone as negative control, for 1 hr prior
to stimulation with NS5A (0.5 mg/ml) for additional 24 h. Supernatants were assayed for IL-10 content by ELISA. Results represent the percentage of
inhibition of IL-10 production, and are the mean 6 SEM of 3 separate experiments. * P,0.01.
doi:10.1371/journal.ppat.1001184.g005
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cells, thus reducing their cytotoxic potential and IFNc production.
Some previous studies have reported defective NK cell function in
HCV infection [47,48,49], although others have not seen this
[5,50,51]. Different methodologies, including the use of total
PBMC or purified NK cells, fresh or cryopreserved cells,
unstimulated or cytokine-stimulated cells, chromium release or
flow cytometry assays, and small sample sizes, might explain why
some of the findings in these studies differed from our own. We
performed all experiments on freshly purified unstimulated NK
Figure 6. Supernatants of HCV-infected Huh-7.5.1 cells reproduce the effect of recombinant NS5A. A) Control PBMCs were cultured for
48 hr in medium alone, in medium containing 0.5 mg/ml of recombinant NS5A, or in medium containing 50% of supernatant from non-infected or
JFH1-replicating Huh-7.5.1 cells (collected at day 3, 13, 15 or 18 post transfection). NKG2D expression on NK cells was analyzed 48 hr later by flow
cytometry. * P,0.05, ** P=10
24 for comparison with the values in medium alone. B) Control monocytes were incubated for 30 min at 4uC with
supernatants from non-infected or JFH1-infected Huh-7.5.1 cells collected at the indicated day post infection, or with 0.5 mg/ml of recombinant NS4
or NS5A proteins as negative and positive controls, respectively. Binding of NS5A to monocytes was revealed by staining with anti-NS5A 9E10
antibody and flow cytometry analysis. Results are expressed as the index of binding ([% binding with culture supernatant - % binding with medium
alone]/% binding with medium alone), and represent mean 6 SEM of 2 independent experiments. C) NKG2D expression on liver-infiltrating NK cells
from HCV patients. Left panel: Representative NKG2D staining in paired circulating and liver-infiltrating NK cells freshly isolated from one chronically
infected HCV patient. Dot plots and corresponding histograms show the frequency of NK cells (boxed CD3-CD56+) and their NKG2D expression. Right
panel: NKG2D staining with anti-NKG2D mAb in liver biopsy from a chronically HCV-infected patient. Results are representative of 4 HCV patients.
Only few NKG2D-positive cells (arrows) are found within a mononuclear infiltrate surrounding a portal tract. Original magnification, 640.
doi:10.1371/journal.ppat.1001184.g006
HCV Evasion to NKG2D-Mediated Response
PLoS Pathogens | www.plospathogens.org 10 November 2010 | Volume 6 | Issue 11 | e1001184cells, and measured NK cell degranulation rather than overall
K562 cell lysis, because it has the advantage to shift the focus from
the fate of target cells to the true response of NK cells, as
previously demonstrated [52].
Different virally encoded products have been shown to impair
NKG2D-mediated detection of infected cells, usually by targeting
the ligands of NKG2D rather than the receptor itself
[14,16,53,54]. HCV only encodes a small number of structural
and non-structural proteins. Consequently, each HCV gene
product must have pleiotropic functions rather than highly
specialized ones. Targeting NKG2D rather than its numerous
ligands is at lower cost for HCV. However, it is likely that HCV
must also target other receptors to escape NK cell recognition.
Indeed, reduced NKp30 levels have been observed on NK cells
from HCV patients [6]. Interestingly, TGFb not only down-
modulates NKG2D, but also reduces expression of NKp30 [23]
and we observed a TGFb-mediated reduction of NKp30 on
control NK cells upon NS5A stimulation. This pleiotropic effect of
TGFb thus represents an economical way for HCV to shift the
overall balance of NK signals towards an inhibitory phenotype.
Our results are in contrast with a recent report by Oliviero et al.
showing an increased proportion of NKG2D+ NK cells in HCV
patients compared with healthy controls [10]. A potential
explanation to this discrepancy is the surprisingly low frequency
Figure 7. NS5A-induced alterations of NKG2D are antagonized by exogenous IL-15. A) IL-15 and TGFb are opposite effects on NKG2D
levels. Left panel: NKG2D staining on NK cells from one HCV patient cultured for 48 days in medium alone or in the presence of 10 ng/ml of IL-15.
Results are representative of independent experiments in 3 patients. Medium and right panels: PBMCs from one control were cultured in the presence
of 10 ng/ml of IL-15 with or without NS5A (0.5 mg/ml) or TGFb-containing serum (S2: 32 ng/ml). Results are representative of independent
experiments in 3 healthy controls. B) Purified NK cells from one HCV patient (upper panel) and one control (lower panel) were cultured for 36 hr with
or without 10 ng/ml of IL-15 and/or 10 ng/ml TGFb, after which lytic capacity to K562 target cells was measured. Numbers in the quadrant are the
percentages of CD107a+ NK cells. Results are representative of 3 independent experiments.
doi:10.1371/journal.ppat.1001184.g007
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study, although NKG2D is usually reported to be constitutively
expressed on all NK cells [12]. In our study, the differences in
patients and controls only affected NKG2D expression levels, but
not the frequency of NKG2D-positive cells.
We show that TGFb production results from NS5A interaction
with the TLR4 complex on monocytes, which leads to a
dysregulated equilibrium of inflammatory cytokines, i.e. increased
IL-10 and defective IL-12 production. IL-10 is a potent suppressor
of TLR-induced inflammatory responses, and an important target
of immune subversion for some pathogens. IL-10 signaling
activates STAT3, which positively regulates TGFb promoter
activity [55]. Previous studied identified that HCV core, NS3 or
NS4, but not E2 protein induced monocyte-derived IL-10
production [56,57]. In the case of core and NS3, this effect was
mediated through TLR2 signaling [58]. Unfortunately, NS5A was
not tested in these studies. We think that NS5A signals through
TLR4 in monocytes, because preincubation with a blocking anti-
TLR4 mAb inhibited NS5A-mediated IL-10 production. Also,
binding experiments showed that NS5A interacted directly with
TLR4 on monocytes. The likelihood of contaminating LPS
contributing to the NS5A-mediated effect was ruled out by the
lack of concomitant IL-12 production. The downregulation of
NKG2D required direct monocyte-NK cell contacts, as it was
completely lost in the Transwell system. This suggests that, in
addition to produce soluble TGFb, NS5A-stimulated monocytes
might express membrane-bound TGFb, which would further
participate in NKG2D modulation through direct contact with
NK cells. In support of this hypothesis, myeloid-derived suppressor
cells (MDSCs), a subpopulation of immature myeloid cells with
suppressor functions, were shown to downregulate NKG2D
expression and inhibit liver NK cell cytotoxicity in cancer-bearing
mice, through expression of membrane-bound TGFb and direct
contact with NK cells [59]. Furthermore, MDSCs were recently
shown to inhibit NK cell functions through direct cell-cell contact
in the context of hepatocellular carcinoma in humans [60,61].
Whether a subpopulation of NS5A-binding monocytes character-
izes MDSCs able to suppress NK cell activity through TGFb
production is under investigation in our laboratory. Further studies
will be needed to determine the role of MDSCs in HCV-infected
patients.
The effect of NS5A on monocytes is reminiscent of other
proteins from persistent viruses. Interaction of HTLV-1 p30
protein with TLR4 signaling stimulates the release of IL-10 and
hampers the release of pro-inflammatory cytokines from
macrophages [25]. HIV Tat-induced IL-10 production by
monocytes is regulated by p38 MAPK [62]. The LMP1 protein
of EBV also induces IL-10 via p38 and PI3 kinase activation
[63]. The vaccinia virus A52R protein activates p38 and JNK,
and promotes TLR4-induced IL-10 production, while inhibit-
ing NFkB-dependent genes IL-8 and RANTES [64]. Human
major group rhinoviruses [26] downmodulate the accessory
function of monocytes by inducing IL-10 production and
inhibiting IL-12 production. Together, those reports and our
findings open the idea that engagement of TLR4 may generate
negative signals that are necessary for immune subversion and
viral persistence.
NS5A is localized in the perinuclear regions of the infected cell,
but is not present in the circulating virions. However, there is now
increasing evidence that HCV mediates hepatocyte apoptosis
[31,32,33,65,66], which may allow HCV proteins to be released in
the extracellular milieu. We observed that supernatants of
Huh7.5.1 human hepatoma cells transfected with the JFH1
infectious replicon reproduced the effect of recombinant NS5A
on NKG2D downmodulation, suggesting that NS5A might be
released in the culture medium from apoptotic cells. However,
direct proof for the presence of NS5A protein in HCV-infected cell
supernatants is still lacking, as it was not accessible by anti-NS5A
mAb in Western blot or depleting experiments. The possibility
that a fraction of bioactive NS5A only becomes liberated after
interaction of the cell debris with monocytes is supported by our
observation of a comparable NS5A binding on monocytes of
recombinant protein and of supernatants from JFH1-replicating
Huh7.5.1 cells.
To reconcile this idea with our finding that the rare NK cells
present in HCV-infected liver expressed high NKG2D levels, one
may envision a scenario in which the local cytokine microenvi-
ronment of the liver sinusoids, in particular IL-15 (which is
produced by Kupffer cells) can inhibit the effect of TGFb and
enhance NKG2D expression. Indeed, IL-15 antagonizes the
TGFb immunosuppressive effects through blockade of the Smad3
signaling pathway [41,42,43]. Expression of IL-15 within HCV-
infected livers was reported to show a sinusoidal distribution [67].
We found that the rare intrahepatic NKG2D-positive cells were
located in sinusoidal tracts, but not in parenchymatous areas or
necroinflammatory lesions where NS5A release by apoptotic
infected cells is likely to occur. Moreover, we showed that IL-15
could fully prevent the TGFb-mediated modulation of NKG2D
and NK cell functions in vitro. A possibility is that once having
migrated to areas of inflammation in the liver, most NK cells
would be induced to apoptosis. This phenomenon might be
favored by the abnormal expression of the Programmed-Death 1
(PD-1) molecule on NK cells, which has been observed in
chronically-infected HCV patients [68]. Only NK cells expressing
high levels of NKG2D would preferentially home to the liver, or
could survive in the liver due to their resistance to apoptosis under
inflammatory conditions. This hypothesis is the matter of current
investigation in our laboratory. That NKG2D levels, either on
peripheral or liver-infiltrating cells, were not correlated with
virological or histological markers of the liver disease has also been
observed by others [39] and might reflect such complex
interactions. Unfortunately, our attempt to clarify whether
increased NKG2D expression on liver NK cells is associated with
enhanced cytotoxic activity was hindered by the highly restricted
access to fresh liver biopsy tissue from chronically infected
patients. The availability of noninvasive biomarkers for first-line
assessment of liver fibrosis has led to a dramatic decrease in the use
of liver biopsy for patients with chronic hepatitis C. Regrettably,
functional analysis of liver-infiltrating immune cells in the few
patients still undergoing liver biopsy is probably not representative
of natural HCV infection.
Altogether, our observations raise the idea that reducing IL-10
and/or TGFb bioavailability could be a suitable means to restore
NK cell functions in chronic hepatitis C. However such approach
could dangerously modify the overall equilibrium between effector
and regulatory mechanisms. Rather, we propose the use of IL-15 -
or biologically active soluble IL-15/IL-15Ra complexes [69] - as
an adjuvant therapeutic agent to restore NKG2D-mediated NK
cell functions. Notably, the pathways triggered by IL-15 receptor
signaling are required for the NKG2D-mediated signal transduc-
tion and cytotoxicity [70]. Jinushi et al. showed that dendritic cells
(DCs) from HCV-infected patients have impaired IL-15 produc-
tion upon stimulation by IFNa [71]. Given the role of NK cells in
promoting optimal initiation of adaptive CD8 T cell responses,
and the role of IL-15 in the proliferation and survival of NK and
CD8 T cells, IL-15 might help not only in establishing strong
innate responses, but also in inducing more robust antiviral CTL
responses.
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Subjects
The HCV viremic patient group consisted of 34 chronically
infected patients (anti-HCV antibodies and HCV RNA positive)
who were naive of treatment, or who discontinued treatment at
least 6 months before study. The HCV aviremic group was
composed of 9 subjects with sustained viral response (SVR)
following IFNa and/or ribavirin therapy, with viremia remaining
undetectable for at least 6 months at the time of study. The main
clinical characteristics of the patients are shown in Table 1.
Patients with primary biliary cirrhosis (n=4) or autoimmune
hepatitis (n=5) were used as non-infectious chronic inflammatory
liver disease controls. An additional series of 11 HCV viremic
patients was studied for paired analysis of circulating and liver-
infiltrating mononuclear cells. The control group consisted of 23
age and sex matched blood donor volunteers seronegative for
HCV.
Ethics statement
The study was performed in accordance with the Declaration of
Helsinki and French legislation, and received approval of the
Grenoble University Hospital ethical committee (03/APTF/1). All
study participants provided written informed consent.
Flow cytometry
Blood samples were processed within 2 h of collection and
PBMCs were separated by Lymphoprep gradient centrifugation
(Biowest). NK cells or monocytes were freshly purified from
PBMCs by negative selection using magnetic microbead separa-
tion kits (Miltenyi Biotec) with purity higher than 90%. Liver-
infiltrating mononuclear cells were isolated from fresh biopsy as
reported [72] and processed immediately for staining and flow
cytometry. Cells were incubated for 20 min at 4uC with
combinations of the following antibodies: CD3-FITC, CD56-PE,
CD8- or CD4-PerCP (BD Biosciences); NKG2D-APC or isotype-
matched control antibodies of irrelevant specificity (BD PharMin-
gen). Cells were fixed in 1% formaldehyde and analyzed on
FACSCalibur (BD Biosciences), collecting a total of 100,000 events
in a live gate, and data were analyzed using FlowJo software.
NK cell degranulation assay and IFNc production
NK cell cytototoxic potential was studied using CD107a as a
marker of degranulation. Freshly isolated NK cells were incubated
in the presence or absence of K562 cells, C1R cells or C1R-MICA
transfectants (a generous gift from A. Toubert, Hopital St-Louis,
Paris, France) as target cells. CD107a-Pe-Cy5 antibody (BD) was
added directly to the tubes at 20 mg/mL. After 1 hour at 37uCi n
5% CO2, brefeldin A (10 mg/ml, Sigma) and monensin (6 mg/ml,
Sigma) were added for additional 5 hr, and cells were stained with
CD3-FITC and CD56-PE antibodies, fixed and analyzed by flow
cytometry. Where indicated, NKG2D blocking antibody (20 mg/
ml, Coulter Immunotech) was added. For intracellular IFNc
analysis, NK cells were incubated for 6 hr with K562 cells, fixed
following staining with anti-CD3 and anti-CD56, permeabilized
with 0.2% saponin and stained with IFNc-PE antibody (BD) for an
additional 30 min.
Cell cultures and reagents
Recombinant TGFb and IL-15 were purchased from R&D
Systems. Cytokine levels were quantified using ELISA (TGFb, IL-
10 and IL-15 quantikine kits from R&D Systems; IL-12 ELISA kit
from Diaclone). Soluble MICA was measured in the sera with a
sandwich ELISA as described [73]. Recombinant soluble MICA
was consistently detected at concentration of 0.2 ng/ml.
The following genotype 1a-derived recombinant HCV proteins
were used: E. Coli-derived full length core, NS3, NS4 and NS5
(Axxora LKT). In confirmatory experiments, we used E. Coli-
derived rNS5A amino acid 2061–2392 (Axxora LKT) and yeast-
derived rNS5 2054–2995 (ibtsystems). Recombinant HCV-E2
protein (Immunodiagnostics) was purified from baculovirus-
infected insect cells. b2microglubulin was used as control for E.
Coli-purified protein. All proteins were used at a final concentra-
tion of 0.1 to 1 mg/ml. Endotoxin levels determined by the limulus
amebocyte lysate assay (BioWhittaker Cambrex) were between
0.05 and 0.2 endotoxin unit/mg protein (0.054 EU/mg for the full
length NS5A protein from Axxora LKT used in most experi-
ments). To ensure that trace amount of endotoxin did not
contribute to the observed responses, rNS5A was subjected to
polymyxin B (10 mg/ml) (Sigma–Aldrich, St. Louis, MO, USA) for
15 min at room temperature.
For blocking experiments, cells were incubated with 10 mg/ml
of neutralizing mAb to TLR4, TLR2 or CD14 (eBioscience),
soluble IL-10 receptor, anti-IL-10 neutralizing antibody (R&D
Systems) before the addition of HCV protein. Isotype-matched
antibodies were used as controls (Coulter Immunotech). Inhibitors
of the signaling molecules JNK (SP600125), p38 (SB203580), PI3
kinase (LY294002), and MEK1 (U0126) were from Calbiochem.
In vitro system of HCV replication
Huh-7.5.1 cells were kindly provided by Pr. Francis V. Chisari
(The Scripps Research Institute, La Jolla, CA), and grown in
Dulbecco’s modified Eagle’s medium-based medium as described
[35]. Productive HCV infection was achieved as described
[34,35]. Briefly, Huh-7.5.1 cells were transfected with genomic
HCV RNA transcribed in vitro from the plasmid pJFH1 [34] (a
kind gift from Takaji Wakita, National Institute of Infectious
Diseases, Tokyo, Japan) used as template, and cells were then
passaged when necessary to maintain subconfluent cultures
throughout the experiment. Cultures were probed for the
frequency of HCV protein-expressing cells by in situ immunoflu-
Table 1. Main characteristics of the patients.
Age (years)* 56±2.5 (20–79)
Gender (M/F) 18/16
HCV genotype (n, %) 1 22 (64.7)
2 and 3 2 (5.9)
4 6 (17.6)
5 4 (11.8)
Viral load (kUI/ml)* 1,1696342 (0.6–8,000)
ALT (xN)* 1.660.15 (1–5)
Liver fibrosis stage (n, %) 0–1 18 (53)
2 5 (14.7)
3 5 (14.7)
4 6 (17.6)
Liver activity score (n, %) 0–1 26 (76.5)
2 2 (5.9)
3 6 (17.6)
*expressed as mean values 6 standard error (range).
doi:10.1371/journal.ppat.1001184.t001
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assessed by focus-formation assay [35].
For binding experiments, monocytes were incubated for 30 min
at 4uC with supernatants from non-infected or JFH1-replicating
Huh-7.5.1 cells, or with 0.5 mg/ml of recombinant NS5A (positive
control) or NS4 (negative control). Where indicated, culture
supernatants were passed through a 0.45-mm filter following low-
speed centrifugation to remove cellular debris.
After washing and blocking with human IgG, cells were
incubated for 40 min at 4uC with the mouse 9E10 mAb specific
for genotype 2a NS5A (a generous gift from C.M. Rice,
Rockefeller University, NY, USA) [74], followed with PE-labeled
goat anti-mouse Ig, and analyzed by flow cytometry.
Immunostaining of liver tissue
Expression of MIC was evaluated on liver biopsy samples
submitted to the Department of Pathology for diagnostic purpose.
Paraffin-embedded liver biopsy sections (12 patients) were stained
with anti-MIC (clone SR99 [75]) or anti-NKG2D (R&D Systems)
mAb, followed with biotinylated goat anti-mouse Ig. For double
immunofluorescence staining, cryosections (3 patients) were
stained overnight at 4uC with anti-HCV-NS5A mAb (clone 7-
D4, BioDesign), followed with FITC-labeled goat anti-mouse IgG,
then incubated with biotinylated anti-MIC mAb, followed with
streptavidin-Cy3. Slides were mounted with DAPI-containing
medium (Vector Laboratories) and analyzed by immunofluores-
cence (Eclipse E888, Nikon) or confocal laser scanning (TCS SPS
AOBS model, Leica) microscopy.
Statistical analysis
All statistical tests were performed using Stata software (version
8.0). Qualitative values between groups were compared using the
chi-square test or Fisher’s exact test, and quantitative values were
compared using the non-parametric Mann-Whitney U test. The
Wilcoxon test was used to compare matched pairs. Correlation
between two variables was determined using Spearman’s coeffi-
cient (rho). Two-sided P values less than 0.05 were considered
significant.
Accession numbers
NKG2D, P26718 (NKG2D_HUMAN); Toll-like receptor 4,
O00206 (TLR4_HUMAN); NS5 protein, Q81596 (Q81596_
9HEPC).
Supporting Information
Figure S1 CD107a expression on NK cells is positively
correlated with NKG2D levels (Spearman rho (r) =0.62,
P=0.008).
Found at: doi:10.1371/journal.ppat.1001184.s001 (4.29 MB TIF)
Figure S2 HCV-NS5A protein downregulates NKp30 levels on
NK cells. Control PBMCs (0.2610
6/ml) were cultured in medium
alone (white bars) or in the presence of 0.5 mg/ml HCV-NS5A
protein (black bars) for 48 h, and NKp30 expression (MFI) was
analyzed on CD3-CD56+ NK cells. Mean 6 SEM values in 4
healthy controls. * P,0.01.
Found at: doi:10.1371/journal.ppat.1001184.s002 (0.72 MB TIF)
Figure S3 NKG2D analysis in a representative liver sample.
Freshly isolated liver infiltrating lymphocytes were stained with
mAb to CD3, CD56 and NKG2D, or isotype control and
analyzed by flow cytometry. A) Isotype control, B) CD3+ CD56- T
lymphocytes, C) CD3-CD56+ NK cells.
Found at: doi:10.1371/journal.ppat.1001184.s003 (0.06 MB TIF)
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